Provide information on new technologies in molecular biology and genetics for investors.
For this specific service, venture capitalists and/or angel investors that are interested in a new technology that is in development and is promising will receive a complete description and explanation of this technology and how it could be used in drug development. Genomic Enterprise can also suggest specific start-up companies that are designing drugs based in genomics and/or in epigenomics.
Develop training for companies and/or academic institutions that are interested in the complex information behind the human genome sequence.
Genomic Enterprise can give training for companies and/or academic institutions such as universities and/or colleges that are interested in understanding several aspects of the available technologies to analyze variations in the human genome and the impact that these variations will have in disease management and treatment.
Provide information on new drugs being tested for cancer and other diseases that have a genetic or genomic/epigenomic component.
Genomic Enterprise will develop projects in a business-to-consumer (B2C) manner in which the customer (investors, venture capitalists, companies and individuals) will buy a report or description about specific drugs that are in clinical trials or just entered the market that were developed by genetic, genomic, and/or epigenomic tools. This report will describe the characterization of the drug, ongoing clinical trials, and toxicity (if already reported). Our company will also try to be very close to the customer to answer questions and give directions such as a guide.
Provide specific presentations and/or workshops about the human genome, genetics, epigenetics and their impact on society and for disease management.
Genomic Enterprise will provide specific presentations and/or workshops about topics related to the human genome, genetics and epigenetics explaining the impact that all this information will have in our society. For example, issues related to how health insurance companies will deal with genetic test and/or predisposition test results will be covered in these presentations. Ethical issues that have emerged after the sequencing of the human genome will be also discussed.
Identify new biotechnology and/or pharmaceutical companies that have promising technologies under development.
Genomic Enterprise will identify promising start-ups in the biotech and pharmaceutical sector for investors in a business-to-business (B2B) manner. A deep research will be done to search for start-ups developing drugs based on molecular studies or molecules that were designed based on a genomic and/or a epigenomic component. After this first step, Genomic Enterprise will generate a list of the most promising companies and explain why their technology in drug development could become a blockbuster. It is important to notice that the reports generated will be just an estimation based on experimental results and published literature about the studied drugs.
Provide scientific advice and help on grant and research proposal writings in the fields of genetics, epigenetics, molecular biology and cancer research.
Genomic Enterprise has also the aim of helping specific researchers in academia and/or industry to write grant proposals based on preliminary data or in new technology development. Our company can give advices based in extensive literature research and compilation. For industry, our company can write grant proposals based on some technologies that are already under development.
Genetic counseling and consultation on companies that can provide specific genetic tests for individuals and/or families.
Genomic Enterprise has the objective of helping individuals and families that want to be tested for specific genetic defects and/or mutations to evaluate the chances of getting a disease. Our job is to find the best genetic test in the USA or even in Europe. Our company will bring together the family and the most sensitive and/or qualified DNA test for specific diseases or conditions. Genomic Enterprise will work as a link between the consumer and the diagnostic test company. In this case, we will provide a consumer-to-business (C2B) service. Our main objective is to make clear to the customer why company A or B will be the best in the market for that specific DNA test. Our knowledge in the genomics and genetics field is a plus in this specific service.